April 5, 2023

The U.S. Food and Drug Administration (FDA) released draft guidance — Marketing Submission Recommendations for a Predetermined Change Control Plan (PCCP) for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions — with public comments due July 3.

The document describes information provided by manufacturers that would enable FDA consideration of planned AI/ML software modifications during device marketing submissions. The PCCP enables downstream improvements to AI/ML software functionality without necessitating additional submissions, provided the future modifications are implemented in accordance with the FDA-vetted plan.

The American College of Radiology® (ACR®) is reviewing the draft guidance. Members interested in providing feedback for potential inclusion in ACR’s future comments should contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • State Legislative Bills Report

    As most state legislatures end their 2025 sessions and look to 2026, ACR staff is looking at how some radiology-specific bills they tracked fared this year.

    Read more
  • Medicare Payment Increase in Final Budget Reconciliation Bill

    The bill includes a 2.5% increase to the Medicare Physician Fee Schedule for calendar year 2026.

    Read more
  • CMS Announces Prior Authorization Test Model

    WiSer is a six-year program that will begin in six states on January 1, 2026. It will introduce prior authorization using AI technology for a select number of services, including some IR procedures.

    Read more